Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
17,819
archived clinical trials in
Brain Cancer

Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
Columbia University Medical Center
mi
from
New York, NY
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
Mount Sinai Hospital
mi
from
New York, NY
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
Mount Sinai Hospital
mi
from
New York, NY
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
New York University Clinical Cancer Center
mi
from
New York, NY
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
New York University Clinical Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
Univ of Rochester Medical Center
mi
from
Rochester, NY
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
Univ of Rochester Medical Center
mi
from
Rochester, NY
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
Stony Brook Medicine
mi
from
Stony Brook, NY
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
Stony Brook Medicine
mi
from
Stony Brook, NY
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
Brain and Spine Surgeons of New York and Northern Westchester Hospital
mi
from
White Plains, NY
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
Brain and Spine Surgeons of New York and Northern Westchester Hospital
mi
from
White Plains, NY
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
Wake Forest Baptist Medical Center
mi
from
Winston-Salem, NC
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
Wake Forest Baptist Medical Center
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
University of Cincinnati Cancer Institute
mi
from
Cincinnati, OH
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
University of Cincinnati Cancer Institute
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
University Hospitals Seidman Cancer Center
mi
from
Cleveland, OH
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
University Hospitals Seidman Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
Ohio State University
mi
from
Columbus, OH
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
Ohio State University
mi
from
Columbus, OH
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
Oklahoma University Health Science Center
mi
from
Oklahoma City, OK
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
Oklahoma University Health Science Center
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
Geisinger Medical Center
mi
from
Danville, PA
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
Geisinger Medical Center
mi
from
Danville, PA
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
Hospital of the University of Pennsylvania
mi
from
Philadelphia, PA
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
Hospital of the University of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
Jefferson Hospital for Neuroscience
mi
from
Philadelphia, PA
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
Jefferson Hospital for Neuroscience
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
Temple University School of Medicine
mi
from
Philadelphia, PA
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
Temple University School of Medicine
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
Rhode Island Hospital
mi
from
Providence, RI
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
Rhode Island Hospital
mi
from
Providence, RI
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
Medical University of South Carolina Hospitals and Clinics
mi
from
Charleston, SC
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
Medical University of South Carolina Hospitals and Clinics
mi
from
Charleston, SC
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
Saint Thomas Research Institute, LLC
mi
from
Nashville, TN
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
Saint Thomas Research Institute, LLC
mi
from
Nashville, TN
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
Baylor Research Institute
mi
from
Dallas, TX
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
Baylor Research Institute
mi
from
Dallas, TX
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
University of Texas Health Science Center at Houston
mi
from
Houston, TX
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
University of Texas Health Science Center at Houston
mi
from
Houston, TX
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
Cancer Therapy & Research at University of Texas Health Science Center San Antonio
mi
from
San Antonio, TX
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
Cancer Therapy & Research at University of Texas Health Science Center San Antonio
mi
from
San Antonio, TX
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
Benaroya Research Institute at Virginia Mason
mi
from
Seattle, WA
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
Benaroya Research Institute at Virginia Mason
mi
from
Seattle, WA
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
Swedish Hospital Neuroscience Research
mi
from
Seattle, WA
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
Swedish Hospital Neuroscience Research
mi
from
Seattle, WA
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
Aurora Saint Lukes Medical Center
mi
from
Milwaukee, WI
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
Aurora Saint Lukes Medical Center
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
City of Hope
mi
from
Duarte, CA
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
City of Hope
mi
from
Duarte, CA
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
University of Colorado Cancer Center
mi
from
Aurora, CO
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
University of Colorado Cancer Center
mi
from
Aurora, CO
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
Moffitt Cancer Center
mi
from
Tampa, FL
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
Moffitt Cancer Center
mi
from
Tampa, FL
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
Washington University School of Medicine
mi
from
St. Louis, MO
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
Washington University School of Medicine
mi
from
St. Louis, MO
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
The Valley Hospital
mi
from
Ridgewood, NJ
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
The Valley Hospital
mi
from
Ridgewood, NJ
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
OhioHealth
mi
from
Columbus, OH
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
OhioHealth
mi
from
Columbus, OH
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
Methodist Hospital
mi
from
Houston, TX
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
Methodist Hospital
mi
from
Houston, TX
Click here to add this to my saved trials
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated:  2/25/2016
Montreal Neurological Institute, McGill University
mi
from
Montreal,
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
Status: Enrolling
Updated: 2/25/2016
Montreal Neurological Institute, McGill University
mi
from
Montreal,
Click here to add this to my saved trials
68Ga-DOTATATE PET Scan in Neuroendocrine Cancer
Use of 68Ga-DOTATATE PET Scanning for Diagnosis and Treatment of Metastatic Neuroendocrine Tumors
Status: Enrolling
Updated:  2/25/2016
Vanderbilt University Medical Center
mi
from
Nashville, TN
68Ga-DOTATATE PET Scan in Neuroendocrine Cancer
Use of 68Ga-DOTATATE PET Scanning for Diagnosis and Treatment of Metastatic Neuroendocrine Tumors
Status: Enrolling
Updated: 2/25/2016
Vanderbilt University Medical Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Safety Study of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma
Phase I Trial of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma
Status: Enrolling
Updated:  2/25/2016
Dartmouth Hitchcock Medical Center
mi
from
Lebanon, NH
Safety Study of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma
Phase I Trial of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma
Status: Enrolling
Updated: 2/25/2016
Dartmouth Hitchcock Medical Center
mi
from
Lebanon, NH
Click here to add this to my saved trials
Safety Study of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma
Phase I Trial of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma
Status: Enrolling
Updated:  2/25/2016
Massey Cancer Center, Virginia Commonwealth University
mi
from
Richmond, VA
Safety Study of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma
Phase I Trial of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma
Status: Enrolling
Updated: 2/25/2016
Massey Cancer Center, Virginia Commonwealth University
mi
from
Richmond, VA
Click here to add this to my saved trials
Donor Atorvastatin Treatment for Preventing Severe Acute Graft-Versus-Host Disease in Patients Undergoing Myeloablative Peripheral Blood Stem Cell Transplantation
Donor Statin Treatment for Prevention of Severe Acute GVHD After Myeloablative Hematopoietic Cell Transplantation
Status: Enrolling
Updated:  2/26/2016
Stanford University Hospitals and Clinics
mi
from
Stanford, CA
Donor Atorvastatin Treatment for Preventing Severe Acute Graft-Versus-Host Disease in Patients Undergoing Myeloablative Peripheral Blood Stem Cell Transplantation
Donor Statin Treatment for Prevention of Severe Acute GVHD After Myeloablative Hematopoietic Cell Transplantation
Status: Enrolling
Updated: 2/26/2016
Stanford University Hospitals and Clinics
mi
from
Stanford, CA
Click here to add this to my saved trials
Donor Atorvastatin Treatment for Preventing Severe Acute Graft-Versus-Host Disease in Patients Undergoing Myeloablative Peripheral Blood Stem Cell Transplantation
Donor Statin Treatment for Prevention of Severe Acute GVHD After Myeloablative Hematopoietic Cell Transplantation
Status: Enrolling
Updated:  2/26/2016
Colorado Blood Cancer Institute
mi
from
Denver, CO
Donor Atorvastatin Treatment for Preventing Severe Acute Graft-Versus-Host Disease in Patients Undergoing Myeloablative Peripheral Blood Stem Cell Transplantation
Donor Statin Treatment for Prevention of Severe Acute GVHD After Myeloablative Hematopoietic Cell Transplantation
Status: Enrolling
Updated: 2/26/2016
Colorado Blood Cancer Institute
mi
from
Denver, CO
Click here to add this to my saved trials
Donor Atorvastatin Treatment for Preventing Severe Acute Graft-Versus-Host Disease in Patients Undergoing Myeloablative Peripheral Blood Stem Cell Transplantation
Donor Statin Treatment for Prevention of Severe Acute GVHD After Myeloablative Hematopoietic Cell Transplantation
Status: Enrolling
Updated:  2/26/2016
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Donor Atorvastatin Treatment for Preventing Severe Acute Graft-Versus-Host Disease in Patients Undergoing Myeloablative Peripheral Blood Stem Cell Transplantation
Donor Statin Treatment for Prevention of Severe Acute GVHD After Myeloablative Hematopoietic Cell Transplantation
Status: Enrolling
Updated: 2/26/2016
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Click here to add this to my saved trials
Post-approval Study of NovoTTF-100A in Recurrent GBM Patients
A Prospective, Non-randomized, Concurrent Control, Open Label, Post-approval Study of NovoTTF-100A in Recurrent GBM Patient
Status: Enrolling
Updated:  2/29/2016
University of Alabama at Birmingham
mi
from
Birmingham, AL
Post-approval Study of NovoTTF-100A in Recurrent GBM Patients
A Prospective, Non-randomized, Concurrent Control, Open Label, Post-approval Study of NovoTTF-100A in Recurrent GBM Patient
Status: Enrolling
Updated: 2/29/2016
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
Post-approval Study of NovoTTF-100A in Recurrent GBM Patients
A Prospective, Non-randomized, Concurrent Control, Open Label, Post-approval Study of NovoTTF-100A in Recurrent GBM Patient
Status: Enrolling
Updated:  2/29/2016
Barrow Neurology Clinics
mi
from
Phoenix, AZ
Post-approval Study of NovoTTF-100A in Recurrent GBM Patients
A Prospective, Non-randomized, Concurrent Control, Open Label, Post-approval Study of NovoTTF-100A in Recurrent GBM Patient
Status: Enrolling
Updated: 2/29/2016
Barrow Neurology Clinics
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Post-approval Study of NovoTTF-100A in Recurrent GBM Patients
A Prospective, Non-randomized, Concurrent Control, Open Label, Post-approval Study of NovoTTF-100A in Recurrent GBM Patient
Status: Enrolling
Updated:  2/29/2016
University of California San Diego, Moores Cancer Center
mi
from
La Jolla, CA
Post-approval Study of NovoTTF-100A in Recurrent GBM Patients
A Prospective, Non-randomized, Concurrent Control, Open Label, Post-approval Study of NovoTTF-100A in Recurrent GBM Patient
Status: Enrolling
Updated: 2/29/2016
University of California San Diego, Moores Cancer Center
mi
from
La Jolla, CA
Click here to add this to my saved trials
Post-approval Study of NovoTTF-100A in Recurrent GBM Patients
A Prospective, Non-randomized, Concurrent Control, Open Label, Post-approval Study of NovoTTF-100A in Recurrent GBM Patient
Status: Enrolling
Updated:  2/29/2016
Keck Medical Center of USC
mi
from
Los Angeles, CA
Post-approval Study of NovoTTF-100A in Recurrent GBM Patients
A Prospective, Non-randomized, Concurrent Control, Open Label, Post-approval Study of NovoTTF-100A in Recurrent GBM Patient
Status: Enrolling
Updated: 2/29/2016
Keck Medical Center of USC
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Post-approval Study of NovoTTF-100A in Recurrent GBM Patients
A Prospective, Non-randomized, Concurrent Control, Open Label, Post-approval Study of NovoTTF-100A in Recurrent GBM Patient
Status: Enrolling
Updated:  2/29/2016
University of Illinois at Chicago
mi
from
Chicago, IL
Post-approval Study of NovoTTF-100A in Recurrent GBM Patients
A Prospective, Non-randomized, Concurrent Control, Open Label, Post-approval Study of NovoTTF-100A in Recurrent GBM Patient
Status: Enrolling
Updated: 2/29/2016
University of Illinois at Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Post-approval Study of NovoTTF-100A in Recurrent GBM Patients
A Prospective, Non-randomized, Concurrent Control, Open Label, Post-approval Study of NovoTTF-100A in Recurrent GBM Patient
Status: Enrolling
Updated:  2/29/2016
University of Kentucky, Markey Cancer Center
mi
from
Lexington, KY
Post-approval Study of NovoTTF-100A in Recurrent GBM Patients
A Prospective, Non-randomized, Concurrent Control, Open Label, Post-approval Study of NovoTTF-100A in Recurrent GBM Patient
Status: Enrolling
Updated: 2/29/2016
University of Kentucky, Markey Cancer Center
mi
from
Lexington, KY
Click here to add this to my saved trials
Post-approval Study of NovoTTF-100A in Recurrent GBM Patients
A Prospective, Non-randomized, Concurrent Control, Open Label, Post-approval Study of NovoTTF-100A in Recurrent GBM Patient
Status: Enrolling
Updated:  2/29/2016
Walter Reed National Military Medical Center
mi
from
Bethesda, MD
Post-approval Study of NovoTTF-100A in Recurrent GBM Patients
A Prospective, Non-randomized, Concurrent Control, Open Label, Post-approval Study of NovoTTF-100A in Recurrent GBM Patient
Status: Enrolling
Updated: 2/29/2016
Walter Reed National Military Medical Center
mi
from
Bethesda, MD
Click here to add this to my saved trials
Post-approval Study of NovoTTF-100A in Recurrent GBM Patients
A Prospective, Non-randomized, Concurrent Control, Open Label, Post-approval Study of NovoTTF-100A in Recurrent GBM Patient
Status: Enrolling
Updated:  2/29/2016
Washington University School of Medicine, Division of Oncology
mi
from
St. Louis, MO
Post-approval Study of NovoTTF-100A in Recurrent GBM Patients
A Prospective, Non-randomized, Concurrent Control, Open Label, Post-approval Study of NovoTTF-100A in Recurrent GBM Patient
Status: Enrolling
Updated: 2/29/2016
Washington University School of Medicine, Division of Oncology
mi
from
St. Louis, MO
Click here to add this to my saved trials
Post-approval Study of NovoTTF-100A in Recurrent GBM Patients
A Prospective, Non-randomized, Concurrent Control, Open Label, Post-approval Study of NovoTTF-100A in Recurrent GBM Patient
Status: Enrolling
Updated:  2/29/2016
The Long Island Brain Tumor Center
mi
from
Lake Success, NY
Post-approval Study of NovoTTF-100A in Recurrent GBM Patients
A Prospective, Non-randomized, Concurrent Control, Open Label, Post-approval Study of NovoTTF-100A in Recurrent GBM Patient
Status: Enrolling
Updated: 2/29/2016
The Long Island Brain Tumor Center
mi
from
Lake Success, NY
Click here to add this to my saved trials